Cisapride reduces neonatal postoperative ileus: Randomised placebo controlled trial

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 77, Issue 2, 1997, Pages

  Lander, A ^a,b   Redkar, R ^a   Nicholls, G ^a   Lawson, A ^a   Choudhury, S R ^a   Corkery, J J ^a   Gornall, P ^a   Buick, R G ^a   Booth, I W ^b  

^a BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Cisapride; Gastroschisis; Postoperative ileus; Prokinesis

Indexed keywords

CISAPRIDE; CLARITHROMYCIN; ERYTHROMYCIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; METOCLOPRAMIDE; MICONAZOLE; PROKINETIC AGENT;

ABDOMINAL SURGERY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FECES ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; ILEUS; NEWBORN; NEWBORN DISEASE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RECTAL DRUG ADMINISTRATION;

EID: 0031419894     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/fn.77.2.F119     Document Type: Article

References (31)

1. Briones ER, Iber FL. Liver and biliary tract changes and injury associated with total parenteral nutrition: pathogenesis and prevention. J Am Coll Nutr 1995;14:219-28.
2. Van Nueten JM, Schuurkes JA. Development of a new gastrointestinal prokinetic; pharmacology of cisapride. J Pharmacol Belgique 1991;46:17-22.
3. Baeyens R, Reyntjens A, Verlinden M. Cisapride accelerates gastric emptying and mouth-to-caecum transit of a barium meal. Eur J Clin Pharmacol 1984;27:315-18.
4. Van Rooy F, Creve U, Verlinden M, Hubens A. Effect of cisapride on the post-cholecystectomy upper gastrointestinal transit time. Int J Clin Pharmacol Ther Toxicol 1988;26:265-8.
5. Boghaert A, Haesaert G, Mourisse P, Verlinden M. Placebo-controlled trial of cisapride in postoperative ileus. Acta Anaesthesiol Belgica 1987;38:95-9.
6. Verlinden M, Michiels G, Boghaert A, de Coster M, Dehertog P. Treatment of postoperative gastrointestinal atony. Br J Surg 1987;74:614-17.
7. Rode H, Stunden RJ, Millar AJ, et al. Esophageal pH assessment of gastroesophageal reflux in 18 patients and the effect of two prokinetic agents: cisapride and metoclopramide. J Pediatr Surg 1987;22:931-4.
8. Hyman PE, McDiarmid SV, Napolitano J, Abrams CE, Tomomasa T. Antroduodenal motility in children with chronic intestinal pseudo-obstruction. J Pediatr 1988;112:899-905.
9. Mearin F, Malagelada JR. Gastroparesis and dyspepsia in patients with diabetes mellitus. Eur J Gastroenterol Hepatol 1995;7:717-23.
10. Longo WE, Vernava AM III. Prokinetic agents for lower gastrointestinal motility disorders. Dis Colon Rectum 1993;36:696-708.
11. Cohen NP, Booth IW, Parashar K, Corkery JJ. Successful management of idiopathic intestinal pseudo-obstruction with cisapride. J Pediatr Surg 1988;23:229-30.
12. Puntis JW, Booth IW, Buick R. Cisapride in neonatal short gut. Lancet 1986;ii:108-9.
13. Tomomasa T, Hyman PE, Itoh K, Hsu JY, Koizumi T, Itoh Z, et al. Gastroduodenal motility in neonates: response to human milk compared with cow's milk formula. Pediatrics 1987;80:434-8.
14. Coombs RC, Buick RG, Gornall PG, Corkery JJ, Booth IW. Intestinal malrotation: the role of small intestinal dysmotiliry in the cause of persistent symptoms. J Pediatr Surg 1991;26:553-6.
15. Peeters TL, Depoortere I. Motilin receptor: a model for development of prokinetics. Dig Dis Sci 1994;39:76S-8S.
16. Armstrong DN, Ballantyne GH, Modlin IM. Erythromycin stimulates ileal motility by activation of dihydropyridine-sensitive calcium channels. J Surg Res 1992;52:40-6.
17. Jameson JS, Rogers J, Misiewicz JJ, Raimundo AH, Henry MM. Oral or intravenous erythromycin has no effect on human distal colonic motility. Aliment Pharmacol Ther 1992;6:589-95.
18. Dive A, Miesse C, Galanti L, Jamart J, Evrard P, Gonzalez M, et al. Effect of erythromycin on gastric motility in mechanically ventilated critically ill patients: a double-blind, randomized, placebo-controlled study. Crit Care Med 1995;23:1356-62.
19. Pilot MA. Macrolides in roles beyond antibiotic therapy. Br J Surg 1994;81:1423-29.
20. Minocha A, Katragadda R, Rahal PS, Ries A. Erythromycin shortens orocaecal transit time in diabetic male subjects: a double-blind placebo-controlled study. Aliment Pharmacol Ther 1995;9:529-33.
21. Verne GN, Eaker EY, Hardy E, Sninsky CA. Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction. Dig Dis Sci 1995;40:892-901.
22. Di Lorenzo C, Flores AF, Tomomasa T, Hyman PE. Effect of erythromycin on antroduodenal motility in children with chronic functional gastrointestinal symptoms. Dig Dis Sci 1994;39:1399-404.
23. Kubota M, Nakamura T, Motokura T, Mori S, Nishida A. Erythromycin improves gastrointestinal motility in extremely low birthweight infants. Acta Paediatrica Japonica 1994;36:198-201.
24. Tomomasa T, Miyazaki M, Koizumi T, Kuroume T. Erythromycin increases gastric antral motility in human premature infants. Biol Neonate 1993;63:349-52.
25. Simkiss DE, Adams IP, Myrdal U, Booth IW. Erythromycin in neonatal postoperative intestinal dysmotility. Arch Dis Child 1994;71:F128-9.
26. Bonacini M, Quiason S, Reynolds M, Gaddis M, Pemberton B, Smith O. Effect of intravenous erythromycin on postoperative ileus. Am J Gastroenterol 1993;88:208-11.
27. Hyman PE, Ahrams CE, Dubois A. Gastric emptying in infants: response to metoclopramide depends on the underlying condition. J Pediatr Gastroenterol Nut 1988;7:181-4.
28. Lewin MB, Bryant RM, Fenrich AL, Grifka RG. Cisapride induced long QT interval. J Pediatr 1996;128:279-81.
29. Bedu A, Lupoglazoff JM, Faure C, et al. Cisaopride high dosage and long QT interval. J Pediatr 1997;130:164.
30. Hanson R, Browne G, Fasher B, et al. Cisapride induced prolonged QT interval: too much of a good thing. J Pediatr 1996;130:164-5.
31. Hedner T, Hedner J, Gelin-Friberg A, et al. Comparative bioavailability of a cisapride suppository and tablet formulation in healthy volunteers. Eur J Clin Pharmacol 1990;38:629-31.